Detalhe da pesquisa
1.
Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia.
Blood
; 143(7): 582-591, 2024 Feb 15.
Artigo
Inglês
| MEDLINE | ID: mdl-37971194
2.
The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.
Blood
; 138(20): 1966-1979, 2021 11 18.
Artigo
Inglês
| MEDLINE | ID: mdl-34132782
3.
Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia.
Blood
; 138(17): 1535-1539, 2021 10 28.
Artigo
Inglês
| MEDLINE | ID: mdl-34289017
4.
Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy.
Haematologica
; 107(5): 1163-1171, 2022 05 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34162182
5.
Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next-generation sequencing in Waldenström macroglobulinaemia.
Br J Haematol
; 194(4): 730-733, 2021 08.
Artigo
Inglês
| MEDLINE | ID: mdl-33713429
6.
BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism.
Blood
; 131(18): 2047-2059, 2018 05 03.
Artigo
Inglês
| MEDLINE | ID: mdl-29496671
7.
Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemia.
Am J Hematol
; 95(4): 372-378, 2020 04.
Artigo
Inglês
| MEDLINE | ID: mdl-31868242
8.
TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia.
Br J Haematol
; 184(2): 242-245, 2019 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30183082
9.
CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib.
Br J Haematol
; 187(3): 356-363, 2019 11.
Artigo
Inglês
| MEDLINE | ID: mdl-31267520
10.
Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia.
Blood
; 129(18): 2519-2525, 2017 05 04.
Artigo
Inglês
| MEDLINE | ID: mdl-28235842
11.
MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival.
Br J Haematol
; 180(3): 374-380, 2018 02.
Artigo
Inglês
| MEDLINE | ID: mdl-29181840
12.
HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.
Blood
; 127(25): 3237-52, 2016 06 23.
Artigo
Inglês
| MEDLINE | ID: mdl-27143257
13.
Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia.
Blood
; 128(6): 827-38, 2016 08 11.
Artigo
Inglês
| MEDLINE | ID: mdl-27301862
14.
Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia.
Br J Haematol
; 172(5): 735-44, 2016 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-26659815
15.
Cell-free DNA analysis for detection of MYD88L265P and CXCR4S338X mutations in Waldenström macroglobulinemia.
Am J Hematol
; 96(7): E250-E253, 2021 07 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33819355
16.
CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors.
Am J Hematol
; 95(4): E95-E98, 2020 04.
Artigo
Inglês
| MEDLINE | ID: mdl-31943341
17.
Spotting the elusive Siberian tiger: Complete response to ibrutinib in a patient with Waldenström Macroglobulinemia.
Am J Hematol
; 2018 May 14.
Artigo
Inglês
| MEDLINE | ID: mdl-29756293
18.
Targeting Myddosome Assembly in Waldenstrom Macroglobulinaemia.
Br J Haematol
; 177(5): 808-813, 2017 06.
Artigo
Inglês
| MEDLINE | ID: mdl-27073043
19.
Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy.
Blood Adv
; 6(3): 1015-1024, 2022 02 08.
Artigo
Inglês
| MEDLINE | ID: mdl-34965304
20.
Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia.
Leukemia
; 36(2): 532-539, 2022 02.
Artigo
Inglês
| MEDLINE | ID: mdl-34531537